ANJESO

Peak

meloxicam

NDAINTRAVENOUSSOLUTION
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam…

Indications (1)

Clinical Trials (5)

NCT03684265Phase 1Completed

A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets

Started Oct 2018
26 enrolled
Healthy
NCT01750931N/ACompleted

This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.

Started Sep 2013
28 enrolled
Arthritis, Rheumatoid
NCT01430559N/ACompleted

Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

Started Oct 2011
408 enrolled
Osteoarthritis of the Knee
NCT02183181Phase 1Completed

Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers

Started Nov 2008
6 enrolled
Healthy
NCT00239382Phase 3Completed

A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis

Started Jul 2004
150 enrolled
Arthritis, Rheumatoid

Loss of Exclusivity

LOE Date
Mar 8, 2039
158 months away
Patent Expiry
Mar 8, 2039

Patent Records (5)

Patent #ExpiryTypeUse Code
10709713
May 26, 2030
U-2750
11253478
May 26, 2030
Product
U-3318
9974746
May 26, 2030
Product
10881663
Mar 8, 2039
U-3038
11458145
Mar 8, 2039
U-3318